Amorsa Therapeutics, Inc.

Foster-miller, Inc.

Drinksavvy, Inc.

Segal Innovations LLC

Acadia Pharmaceuticals Inc.

Eikos, Inc.

Veroscience LLC

Nelson Landrau

Anthony H Cincotta

Alex Nivorozhkin

Robert F Kovar

Paul Osenar

Leslie S Rubin

Michael T Abramson

John C MacDonald

Nese Orbey

Brendan Walker

Richard M Formato

Bruce Segal

Paul J Glatkowski

Brian P Farrell

William E Dorogy

Jeffrey L Conroy

Joseph W Piche

Elizabeth Yost

David H Landis, Jr

William Slager

William E Dorogy, Jr

The present invention is directed to novel neuro-attenuating norketamine (NANKET) compounds according to any one of formulas (I—shown below), (I-A) and (I-B), or any of the compounds described in Tables A-D, or in any of the Examples provided herein, and pharmaceutically acceptable salts thereof, novel pharmaceutical formulations and novel methods of uses thereof. The present invention also features novel oral neuro-attenuating ketamine (NAKET) and neuro-attenuating norketamine (NANKET) modified-release pharmaceutical formulations, and novel methods of administration thereof, which ensure the steady release of a therapeutically effective amount of ketamine, norketamine, or derivatives thereof from the oral modified-release pharmaceutical formulations without neurologically toxic spikes in plasma concentration of the ketamine, norketamine, or derivatives during the release periods.

Neuro-attenuating ketamine and norketamine compounds, derivatives thereof, and methods

A medical device may comprise a body including a mixture of polyvinylpyrrolidone ('PVP') and mitomycin. The medical device may be in any size or shape such that the medical device may be inserted into living tissue, including, but not limited to, a lacrimal punctal plug and a stent. The mixture of PVP and mitomycin may be coated on a portion of the medical device, contained within a cavity on the medical device, disposed on the surface of the medical device or configured as part of the medical device such that the mixture of PVP and mitomycin can be delivered to tissue.

Bio-adhesive dissolving compounds and device

The present invention is directed to novel neuro-attenuating norketamine (NANKET) compounds according to any one of formulas (I&#x2014;shown below), (I-A) and (I-B), or any of the compounds described in Tables A-D, or in any of the Examples provided herein, and pharmaceutically acceptable salts thereof, novel pharmaceutical formulations and novel methods of uses thereof. The present invention also features novel oral neuro-attenuating ketamine (NAKET) and neuro-attenuating norketamine (NANKET) modified-release pharmaceutical formulations, and novel methods of administration thereof, which ensure the steady release of a therapeutically effective amount of ketamine, norketamine, or derivatives thereof from the oral modified-release pharmaceutical formulations without neurologically toxic spikes in plasma concentration of the ketamine, norketamine, or derivatives during the release periods. 

The present invention is directed to oral neuro-attenuating ketamine (NAKET) tablet formulations, and methods of administration, which ensure the steady release of a therapeutically effective concentration of ketamine from an oral tablet without neurologically toxic spikes in ketamine concentration. In particular, the present invention provides single layer oral tablet formulation of NAKET. In a specific embodiment, the NAKET tablet formulation, and methods of administration provide steady administration of NAKET to a subject for 24 hours or greater, for example, up to 36 hours, after a single administration event.

Single-layer oral dose of neuro-attenuating ketamine

The present invention is directed to novel neuro-attentuating norketamine (NANKET) compounds according to any one of formulas (I&#x2014;shown below), (I-A) and (I-B), or any of the compounds described in Tables A-D, or in any of the Examples provided herein, and pharmaceutically acceptable salts thereof, novel pharmaceutical formulations and novel methods of uses thereof. The present invention also features novel oral neuro-attenuating ketamine (NAKET) and neuro-attenuating norketamine (NANKET) modified-release pharmaceutical formulations, and novel methods of administration thereof, which ensure the steady release of a therapeutically effective amount of ketamine, norketamine, or derivatives thereof from the oral modified-release pharmaceutical formulations without neurologically toxic spikes in plasma concentration of the ketamine, norketamine, or derivatives during the release periods. 

Single layer oral dose of neuro-attenuating ketamine

An apparatus is configured to detect a beverage that is contaminated with a substance. The apparatus may include a testing material, wherein the testing material may comprise a cavity having a complementary shape to a molecule associated with the substance. The apparatus may include a taste substance filling the cavity, wherein the taste substance filling the cavity may bleed out into the beverage when the molecule associated with the substance in the beverage replaces the taste substance filling the cavity, wherein a taste of the beverage may change when the taste substance bleeds out into the beverage as an indicator that the substance is present in the beverage.

System and method for detection of a contaminated beverage

The present invention is directed to novel neuro-attentuating norketamine (NANKET) compounds according to any one of formulas (I-shown below), (I-A) and (I-B)), or any of the compounds described in Tables A-D, or in any of the Examples provided herein, and pharmaceutically acceptable salts thereof, novel pharmaceutical formulations and novel methods of uses thereof. The present invention also features novel oral neuro-attenuating ketamine (NAKET) and neuro-attenuating norketamine (NANKET) modified-release pharmaceutical formulations, and novel methods of administration thereof, which ensure the steady release of a therapeutically effective amount of ketamine, norketamine, or derivatives thereof from the oral modified-release pharmaceutical formulations without neurologically toxic spikes in plasma concentration of the ketamine, norketamine, or derivatives during the release periods. 

An apparatus may be configured to test a beverage, the apparatus may include but is not limited to, a food container, wherein the food container includes a material. An indicator may be combined with at least a portion of the material of the food container, wherein the indicator may be associated with a brand profile that may identify a brand of the food, wherein the indicator may visibly react when the indicator is contacted with the food to show whether the food is identified as the brand of the food, and wherein the visible reaction may be shown on at least the portion of the material of the food container via the indicator combined with at least the portion of the material of the food container.

An apparatus may be configured to test a beverage, the apparatus may include but is not limited to, a beverage container that may be configured to hold a beverage, wherein the beverage container may include a material. An indicator may be chemically bonded to at least a portion of the material of the beverage container, wherein at least the portion of the material of the beverage container may include the indicator, wherein the indicator may be associated with at least part of a brand profile to identify a brand of the beverage, wherein the indicator may visibly react when the indicator is contacted with the beverage to show whether the beverage may be identified as the brand of the beverage, and wherein the visible reaction may be shown on at least the portion of the material of the beverage container via the indicator chemically bonded to at least the portion of the material of the beverage container.

The invention is directed to conformal coatings that provide excellent shielding against electromagnetic interference (EMI). A conformal coating comprises an insulating layer and a conducting layer containing electrically conductive material. The insulating layer comprises materials for protecting a coated object. The conducting layer comprises materials that provide EMI shielding such as carbon black, carbon buckeyballs, carbon nanotubes, chemically-modified carbon nanotubes and combinations thereof. The insulating layer and the conductive layer may be the same or different, and may be applied to an object simultaneously or sequentially. Accordingly, the invention is also directed to objects that are partially or completely coated with a conformal coating that provides EMI shielding.

Conformal coatings comprising carbon nanotubes

The present invention relates to composite solid polymer electrolyte membranes (SPEMs) which include a porous polymer substrate interpenetrated with an ion-conducting material. SPEMs of the present invention are useful in electrochemical applications, including fuel cells and electrodialysis.

Growing community of inventors

Marlborough, MA, United States of America

Nelson Landrau